Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Taplin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Urology|December 24, 1997
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapyR Joyce, M A Fenton, P Rode, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group BD M Savarese, S Halabi, V Hars, et al.
The New England Journal of Medicine|May 25, 1995
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancerM E Taplin, G J Bubley, T D Shuster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2015
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaJ Bellmunt, S A Mullane, L Werner, et al.
Prostate Cancer and Prostatic Diseases|May 29, 2013
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancerM D Galsky, W Xie, M Nakabayashi, et al.
The Journal of Urology|June 18, 2004
Monitoring the serological proteome: the latest modality in prostate cancer detectionJ A Mobley, Y W Lam, K M Lau, et al.
ESMO Open|January 23, 2025
Association between DNA damage repair alterations and outcomes to <sup>177</sup>Lu-PSMA-617 in advanced prostate cancerA Rami, N S Rashid, C Zhong, et al.
Prostate Cancer and Prostatic Diseases|August 6, 2014
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancerR R McKay, K A Zukotynski, L Werner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
The Prostate|May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala VariantA Mandl, M L Zahurak, N A Metri, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Urology|December 24, 1997
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapyR Joyce, M A Fenton, P Rode, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group BD M Savarese, S Halabi, V Hars, et al.
The New England Journal of Medicine|May 25, 1995
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancerM E Taplin, G J Bubley, T D Shuster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2015
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaJ Bellmunt, S A Mullane, L Werner, et al.
Prostate Cancer and Prostatic Diseases|May 29, 2013
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancerM D Galsky, W Xie, M Nakabayashi, et al.
The Journal of Urology|June 18, 2004
Monitoring the serological proteome: the latest modality in prostate cancer detectionJ A Mobley, Y W Lam, K M Lau, et al.
ESMO Open|January 23, 2025
Association between DNA damage repair alterations and outcomes to <sup>177</sup>Lu-PSMA-617 in advanced prostate cancerA Rami, N S Rashid, C Zhong, et al.
Prostate Cancer and Prostatic Diseases|August 6, 2014
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancerR R McKay, K A Zukotynski, L Werner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
The Prostate|May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala VariantA Mandl, M L Zahurak, N A Metri, et al.
Pageof 2